Skip to main content
Equibles
EW logo

EW · Edwards Lifesciences Corp · Earnings Call Transcripts & Audio

Track EW — free

Use EW with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EW.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$86.32 -1.76 (-2.00%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$49.74B
Shares
576.40M
Volume · Sep 30 4.8M Avg daily vol (3M) 3.86M

Edwards Lifesciences Corp Earnings Call Transcripts

Quarterly earnings calls for Edwards Lifesciences Corp (EW), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲0.7% $1.32B $343.50M '22 Q3 22-10-27 ▼67.7% $429.90M $398.40M '22 Q4 23-01-31 ▼8.9% $1.22B $340.50M '23 Q1 23-04-26 ▼6.9% $1.28B $307.10M '23 Q2 23-07-26 ▼5.7% $1.24B $384.90M '23 Q3 23-10-25 ▲194.6% $1.27B $369.90M '23 Q4 24-02-06 ▲8.9% $1.33B $351.90M '24 Q1 24-04-25 ▲7.1% $1.37B $366.30M '24 Q2 24-07-24 ▲8.9% $1.35B $3.07B '24 Q3 24-10-24 ▲9.4% $1.39B $385.60M '24 Q4 25-02-11 ▲6.2% $1.41B $358.00M '25 Q1 25-04-23 ▲11.9% $1.53B $333.20M '25 Q2 25-07-24 ▲14.7% $1.55B $291.10M '25 Q3 25-10-30 ▲13.3% $1.57B $91.20M '25 Q4 26-02-10 ▲16.7% $1.65B $380.70M '26 Q1 26-04-23 LATEST ▲13.6% $1.74B $241.90M '26 Q2 26-07-23
Earnings call
FY26 · Q2
2026-07-23
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Transcript
Confident tone TAVR franchise and Sapien platform PROGRESS trial readout TMTT (Pascal, Evoque, SAPIEN M3) momentum
Revenue
$1.74B
▲ 13.6% YoY
Diluted EPS
$0.42
▼ 25% YoY
Gross margin
77.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-23
Edwards Lifesciences Corp (EW) Q1 2026 Earnings Call Transcript
Confident tone TAVR growth and market momentum TMTT (mitral and tricuspid) portfolio Surgical structural heart
Revenue
$1.65B
▲ 16.7% YoY
Diluted EPS
$0.66
▲ 8.2% YoY
Gross margin
78.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-10
Edwards Lifesciences Corp (EW) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-10
Edwards Lifesciences Corp (EW) Q4 2025 Earnings Call Transcript
Confident tone TAVR Growth Momentum and Durability Data Early TAVR and Asymptomatic Indication TMTT Portfolio Expansion
Revenue
$1.57B*
▲ 13.3% YoY
Gross margin
78.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Edwards Lifesciences Corp (EW) Q3 2025 Earnings Call Transcript
Confident tone TAVR franchise growth and clinical evidence TMTT (Mitral and Tricuspid) portfolio expansion R&D discipline and margin expansion
Revenue
$1.55B
▲ 14.7% YoY
Diluted EPS
$0.50
▼ 90.3% YoY
Gross margin
77.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-24
Edwards Lifesciences Corp (EW) Q2 2025 Earnings Call Transcript
Confident tone TAVR growth and SAPIEN platform TMTT (mitral/tricuspid) franchise leadership TAVR leadership transition
Revenue
$1.53B
▲ 11.9% YoY
Diluted EPS
$0.56
▼ 8.2% YoY
Gross margin
77.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-23
Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Transcript
Confident tone TMTT momentum and product approvals Tariffs and financial guidance TAVR growth and early TAVR expansion
Revenue
$1.41B
▲ 6.2% YoY
Diluted EPS
$0.61
▲ 5.2% YoY
Gross margin
78.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-11
Edwards Lifesciences Corp (EW) Q4 2024 Earnings Call Transcript
Confident tone TMTT (mitral and tricuspid) momentum TAVR growth and early TAVR catalyst 2025 financial guidance and outlook
Revenue
$1.39B
▲ 9.4% YoY
Diluted EPS
$0.65
▲ 6.6% YoY
Gross margin
78.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-24
Edwards Lifesciences Corp (EW) Q3 2024 Earnings Call Transcript
Confident tone TAVR performance and outlook TMTT growth (PASCAL, EVOQUE, SAPIEN M3) Portfolio reshaping and Critical Care divestiture
Revenue
$1.35B
▲ 8.9% YoY
Diluted EPS
$5.13
▲ 714.3% YoY
Gross margin
80.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-24
Edwards Lifesciences Corp (EW) Q2 2024 Earnings Call Transcript
Cautious tone TAVR sales shortfall and US hospital workflow pressure TMTT growth and product launches JenaValve and Endotronix acquisitions
Revenue
$1.37B
▲ 7.1% YoY
Diluted EPS
$0.61
▲ 22% YoY
Gross margin
79.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Edwards Lifesciences Corp (EW) Q1 2024 Earnings Call Transcript
Confident tone TAVR growth and SAPIEN platform TMTT (mitral and tricuspid) growth Critical Care spin-off
Revenue
$1.33B
▲ 8.9% YoY
Diluted EPS
$0.58
▲ 3.6% YoY
Gross margin
78.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-06
Edwards Lifesciences Corp (EW) Q4 2023 Earnings Call Transcript
Confident tone TAVR growth and leadership TMTT portfolio expansion EVOQUE FDA approval and launch
Revenue
$1.27B
▲ 194.6% YoY
Diluted EPS
$0.61
Gross margin
80.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-25
Edwards Lifesciences Corp (EW) Q3 2023 Earnings Call Transcript
Revenue
$1.24B
▼ 5.7% YoY
Diluted EPS
$0.63
▲ 14.5% YoY
Gross margin
79.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-07-26
Edwards Lifesciences Corp (EW) Q2 2023 Earnings Call Transcript
Revenue
$1.28B
▼ 6.9% YoY
Diluted EPS
$0.50
▼ 23.1% YoY
Gross margin
80.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Edwards Lifesciences Corp (EW) Q1 2023 Earnings Call Transcript
Revenue
$1.22B
▼ 8.9% YoY
Diluted EPS
$0.56
▼ 5.1% YoY
Gross margin
81.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-31
Edwards Lifesciences Corp (EW) Q4 2022 Earnings Call Transcript
Revenue
$429.90M*
▼ 67.7% YoY
Gross margin
123.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Edwards Lifesciences Corp (EW) Q3 2022 Earnings Call Transcript
Revenue
$1.32B
▲ 0.7% YoY
Diluted EPS
$0.55
▲ 1.9% YoY
Gross margin
80.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Edwards Lifesciences Corp (EW) Q2 2022 Earnings Call Transcript
Revenue
$1.37B
▼ 0.2% YoY
Diluted EPS
$0.65
▼ 16.7% YoY
Gross margin
80.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-26
Edwards Lifesciences Corp (EW) Q1 2022 Earnings Call Transcript
Revenue
$1.34B
▲ 10.2% YoY
Diluted EPS
$0.59
▲ 9.3% YoY
Gross margin
77.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-26
Edwards Lifesciences Corp (EW) Q4 2021 Earnings Call Transcript
Revenue
$1.33B*
▲ 11.6% YoY
Gross margin
76.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Edwards Lifesciences Corp (EW) Q3 2021 Earnings Call Transcript
Revenue
$1.31B
▲ 14.8% YoY
Diluted EPS
$0.54
▲ 3.8% YoY
Gross margin
76.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Edwards Lifesciences Corp (EW) Q2 2021 Earnings Call Transcript
Revenue
$1.38B
▲ 48.8% YoY
Diluted EPS
$0.78
Gross margin
75.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-20
Edwards Lifesciences Corp (EW) Q1 2021 Earnings Call Transcript
Revenue
$1.22B
▲ 7.8% YoY
Diluted EPS
$0.54
▲ 10.2% YoY
Gross margin
75.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-27
Edwards Lifesciences Corp (EW) Q4 2020 Earnings Call Transcript
Revenue
$1.19B
▲ 1.5% YoY
Diluted EPS
$0.49
▲ 11.4% YoY
Gross margin
75.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-21
Edwards Lifesciences Corp (EW) Q3 2020 Earnings Call Transcript
Revenue
$1.14B
▲ 4.3% YoY
Diluted EPS
$0.52
▲ 20.9% YoY
Gross margin
75.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-23
Edwards Lifesciences Corp (EW) Q2 2020 Earnings Call Transcript
Revenue
$925.00M
▼ 14.9% YoY
Diluted EPS
$-0.20
▼ 152.6% YoY
Gross margin
74.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-23
Edwards Lifesciences Corp (EW) Q1 2020 Earnings Call Transcript
Revenue
$1.13B
▲ 13.7% YoY
Diluted EPS
$0.49
▲ 25.6% YoY
Gross margin
76.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-30
Edwards Lifesciences Corp (EW) Q4 2019 Earnings Call
Revenue
$1.17B
▲ 20.1% YoY
Diluted EPS
$0.44
▲ 4300% YoY
Gross margin
75.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 earnings calls
Key facts CIK 1099800 CUSIP 28176E108 13F (30d) 34 filings 21 filers Visit website Investor relations